BerandaKYNB • NASDAQ
add
Kyntra Bio Inc
Tutup sebelumnya
$7,10
Rentang hari
$7,01 - $7,40
Rentang tahun
$6,32 - $9,70
Kapitalisasi pasar
28,37 jt USD
Volume Rata-Rata
39,56 rb
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Berita pasar
NDAQ
1,76%
2,38%
Keuangan
Laporan Laba Rugi
Pendapatan
Penghasilan bersih
| (USD) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 1,28 jt | -59,27% |
Biaya operasional | 7,25 jt | -13,13% |
Penghasilan bersih | -14,22 jt | -179,08% |
Margin laba bersih | -1,11 rb | -294,14% |
Penghasilan per saham | -3,51 | -75,50% |
EBITDA | -13,51 jt | 49,92% |
Tarif pajak efektif | 0,00% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 88,98 jt | 76,26% |
Total aset | 119,59 jt | -44,25% |
Total liabilitas | 115,12 jt | -71,09% |
Total ekuitas | 4,48 jt | — |
Saham yang beredar | 4,05 jt | — |
Harga terhadap nilai buku | -0,96 | — |
Tingkat pengembalian aset | -26,34% | — |
Tingkat pengembalian modal | -110,83% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Penghasilan bersih | -14,22 jt | -179,08% |
Kas dari operasi | -18,33 jt | 39,84% |
Kas dari investasi | -51,71 jt | -3.101,28% |
Kas dari pembiayaan | -14,00 rb | -380,00% |
Perubahan kas bersih | -70,10 jt | -143,20% |
Arus kas bebas | -10,14 jt | 90,52% |
Tentang
Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate.
On January 8, 2026, FibroGen changed its name to Kyntra Bio and ticker symbol to KYNB. Wikipedia
Didirikan
1 Jan 1993
Kantor pusat
Situs
Karyawan
34